Also known as: Intellia
Intellia Therapeutics is a clinical-stage gene editing company developing potentially curative genome-editing treatments. Its pipeline includes in vivo CRISPR-based programs such as NTLA-2001 and NTLA-2002, with additional partnered cell therapy and genomic medicine efforts.
The FDA removed the clinical hold on Intellia Therapeutics' Phase 3 trial of nexiguran ziclumeran for transthyretin amyloidosis with cardiomyopathy. The hold was imposed in October following liver safety concerns in one patient.
The FDA removed the clinical hold on Intellia Therapeutics' MAGNITUDE-2 Phase 3 trial of nexiguran ziclumeran for ATTRv-PN, allowing patient enrollment and dosing to resume with enhanced safety monitoring.
